Src Kinase Inhibitors: Promising Cancer Therapeutics?
The DOI matches its Crossref record.
Abstract
Src is the cellular counterpart of the first identified viral oncogene v-Src. It forms part of a large family of nonreceptor tyrosine kinases that have been extensively studied over the last few decades. This has led to the realization that Src can regulate a number of signaling pathways that impact on the behavior of tumor cells, including proliferation, survival, migration, invasion, and angiogenesis. There are currently four Src inhibitors (dasatinib, saracatinib, bosutinib, and KX01) in clinical development, and although there is a plethora of information on their activity in preclinical models their clinical efficacy has been disappointing. Here we review the current status of the Src inhibitors and highlight the difficulties involved in assessing these therapeutics in the clinical setting. In the future it will be important to combine our knowledge of basic Src biology with the use of appropriate preclinical models to aid the design of clinical trials. Taking this integrated approach will hopefully help to realize the true potential of Src kinase inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
E-cadherin–integrin crosstalk in cancer invasion and metastasis
Canel, M., Serrels, A., Frame, M. C., & Brunton, V. G. (2013) · Journal of Cell Science · doi:10.1242/jcs.100115 · Cited by 623
Self-citationCook, D. R., Rossman, K. L., & Der, C. J. (2014) · Oncogene · doi:10.1038/onc.2013.362 · Cited by 378
Src family kinases: at the forefront of platelet activation
Senis, Y. A., Mazharian, A., & Mori, J. (2014) · Blood · doi:10.1182/blood-2014-01-453134 · Cited by 296
Integrin signalling regulates YAP/TAZ to control skin homeostasis
Elbediwy, A., Vincent-Mistiaen, Z. I., Spencer-Dene, B., Stone, R. K., Boeing, S., Wculek, S. K., Cordero, J., Tan, E. H., Ridgway, R., Brunton, V. G., et al. (2016) · Development · doi:10.1242/dev.133728 · Cited by 291
Self-citationGenotoxicity and carcinogenicity risk of carbon nanotubes
Toyokuni, S. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.05.011 · Cited by 117
Metadata
- Authors
- Creedon, H., & Brunton, V. G.
- Venue
- Critical Reviews™ in Oncogenesis
- Publisher
- Begell House
- Published
- 2012
- Volume
- 17
- Issue
- 2
- Pages
- 145-159
- ISSN
- 0893-9675 (ISSN-L)
- OpenAlex
- W2078155300
- Cited by
- 69
- References
- 0
- FWCI
- 5.61
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Src Kinase Inhibitors: Promising Cancer Therapeutics? https://app.cochat.ai/papers/10.1615/critrevoncog.v17.i2.20
- The paper
- Creedon, H., & Brunton, V. G. (2012). Src Kinase Inhibitors: Promising Cancer Therapeutics? Critical Reviews™ in Oncogenesis. https://doi.org/10.1615/critrevoncog.v17.i2.20
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.